Open use of natalizumab. Neutralising antibodies and clinical data;Natalizumab im klinischen alltag. Neutralisierende antikörper und klinische daten

Nervenarzt

Volumn 79, Issue 6, 2008, Pages 716-719

  Haghikia, A ^a   Fischer, M ^a   Hellwig, K ^a   Linker, R ^a   Chan, A ^a   Hohlfeld, R ^b   Gold, R ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Immune therapy; Natalizumab; Relapsing remitting multiple sclerosis

Indexed keywords

NATALIZUMAB; NEUTRALIZING ANTIBODY;

ALLERGIC REACTION; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOTHERAPY; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MONOTHERAPY; MULTIPLE SCLEROSIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 44949195688     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-008-2464-8     Document Type: Article

References (5)

1. Gold R, Jawad A, Miller DH et al. (2007) Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol 187: 156-158
2. Polman CH, O'Connor PW, Havrdova E et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910
3. Rice GP, Hartung HP, Calabresi PA (2005) Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64: 1336-1342
4. Calabresi PA, Giovannoni G, Confavreux C et al. (2007) The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69: 1391-1403
5. Rudick RA, Stuart WH, Calabresi PA et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354: 911-923